S. K. Kunutsor, R. Rikhtehgaran, Y. Xu, et al., “Associations of Multimarkers of Metabolic Malnutrition and Inflammation With All‐Cause Mortality and Their Interplay With Thyroid Function,” Endocrinology, Diabetes & Metabolism 9, no. 2 (2026): e70162, 10.1002/edm2.70162.
In Table 1 of the above article, the values for GlycA and triglycerides were incorrectly swapped between the alive and dead groups. This error is confined to Table 1. The corrected Table 1 is provided below and does not affect the analyses, results, interpretation, or conclusions of the article.
TABLE 1.
Baseline characteristics of participants overall and by status at end of follow‐up.
| Variable | Overall (N = 5446) mean (SD) or median (IQR) | Status at end of follow‐up | p | |
|---|---|---|---|---|
| Dead (N = 806) mean (SD) or median (IQR) | Alive (N = 4640) mean (SD) or median (IQR) | |||
| MVX score | 44.9 (9.0) | 48.8 (9.0) | 44.2 (8.9) | < 0.001 |
| IVX score | 39.2 (10.5) | 43.6 (10.3) | 38.4 (10.4) | < 0.001 |
| MMX score | 54.3 (6.4) | 55.6 (6.7) | 54.0 (6.3) | < 0.001 |
| GlycA (μmol/L) | 373 (336, 416) | 395 (357, 437) | 369 (333, 410) | < 0.001 |
| Small HDL particles (μmol/L) | 15.92 (2.43) | 15.28 (2.44) | 16.03 (2.42) | < 0.001 |
| Leucine (μmol/L) | 104.42 (27.12) | 106.46 (28.32) | 104.07 (26.89) | 0.02 |
| Valine (μmol/L) | 201.60 (38.36) | 207.97 (38.66) | 200.49 (38.21) | < 0.001 |
| Isoleucine (μmol/L) | 58.43 (14.67) | 61.99 (15.56) | 57.81 (14.42) | < 0.001 |
| Citrate (μmol/L) | 2.08 (0.48) | 2.28 (0.53) | 2.05 (0.46) | < 0.001 |
| FT3 (pmol/L) | 4.89 (0.74) | 4.85 (1.05) | 4.89 (0.67) | 0.14 |
| FT4 (pmol/L) | 15.59 (2.33) | 15.84 (2.50) | 15.54 (2.30) | < 0.001 |
| TSH (mU/L) | 1.62 (1.11, 2.35) | 1.55 (1.02, 2.26) | 1.63 (1.13, 2.37) | 0.004 |
| TPOAb positivity, n (%) | 593 (10.9) | 73 (9.1) | 520 (11.2) | 0.08 |
| Questionnaire | ||||
| Age (years) | 54 (12) | 67 (10) | 51 (11) | < 0.001 |
| Males, n (%) | 2717 (49.9) | 539 (66.9) | 2178 (46.9) | < 0.001 |
| Alcohol consumers, n (%) | 4086 (75.0) | 565 (70.1) | 3521 (75.9) | < 0.001 |
| Smokers, n (%) | < 0.001 | |||
| Never smokers | 1556 (28.6) | 132 (16.4) | 1424 (30.7) | |
| Former smokers | 2343 (43.0) | 427 (53.0) | 1916 (41.3) | |
| Light current smokers | 595 (10.9) | 93 (11.5) | 502 (10.8) | |
| Heavy current smokers | 952 (17.5) | 154 (19.1) | 798 (17.2) | |
| History of T2D, n (%) | 331 (6.1) | 124 (15.4) | 207 (4.5) | < 0.001 |
| History of CVD, n (%) | 155 (2.8) | 73 (9.1) | 82 (1.8) | < 0.001 |
| Use of antihypertensive medication, n (%) | 1013 (18.6) | 347 (43.1) | 666 (14.4) | < 0.001 |
| Physical measurements | ||||
| BMI (kg/m2) | 26.7 (4.3) | 27.3 (4.3) | 26.6 (4.3) | < 0.001 |
| SBP (mmHg) | 126 (19) | 137 (21) | 124 (17) | < 0.001 |
| DBP (mmHg) | 73 (9) | 76 (9) | 73 (9) | < 0.001 |
| Lipid and renal markers | ||||
| Total cholesterol (mmol/L) | 5.43 (1.05) | 5.42 (1.10) | 5.43 (1.04) | 0.73 |
| HDL‐C (mmol/L) | 1.26 (0.31) | 1.21 (0.33) | 1.27 (0.31) | < 0.001 |
| Triglycerides (mmol/L) | 1.13 (0.81, 1.62) | 1.23 (0.90, 1.72) | 1.11 (0.80, 1.60) | < 0.001 |
| Creatinine (mg/dl) | 0.83 (0.23) | 0.92 (0.45) | 0.81 (0.16) | < 0.001 |
| Cystatin C (mg/L) | 0.91 (0.21) | 1.08 (0.35) | 0.88 (0.16) | < 0.001 |
| Estimated GFR (ml/min/1.73m2) | 84.1 (10.5) | 74.8 (15.8) | 85.7 (8.3) | < 0.001 |
Note: Continuous variables are reported as mean (SD) or median (interquartile range) and categorical variables are reported as n (%). Former smokers were those who were non‐smokers at the time of study inclusion but had ever smoked in their life; current smokers were those who reported smoking at the time of inclusion; light current smokers were current smokers who reported smoking 10 cigarettes or less per day; and heavy current smokers were current smokers who reported smoking more than 10 cigarettes per day.
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; FT3, free triiodothyronine; FT4, free thyroxine; GFR, glomerular filtration rate (as calculated using the chronic kidney disease epidemiology collaboration combined creatinine–cystatin C equation); HDL‐C, high density lipoprotein cholesterol; IQR, interquartile range; IVX, the inflammation vulnerability index; MMX, the metabolic malnutrition index; MVX, the metabolic vulnerability index; SBP, systolic blood pressure; SD, standard deviation; T2D, type 2 diabetes; TPOAb, thyroid peroxidase antibodies; TSH, thyroid‐stimulating hormone.
We apologize for this error.